Top Markets
Coin of the day
IDL Diagnostics AB (publ) IDL Diagnostics AB (publ)

IDL Diagnostics AB (publ)

IDLDX
Rank in Stocks #32452
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops... Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Share Price
$0.04367217
Last synced: 2026-08-17
Market Cap
$10.06M
Change (1 day)
3.99%
Change (1 year)
-26.77%
Country
SE
Trade IDL Diagnostics AB (publ) (IDLDX)

Category

Earnings for IDL Diagnostics AB (publ) (IDLDX)
Earnings in 2026 TTM: 0
According to IDL Diagnostics AB (publ) latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for IDL Diagnostics AB (publ) from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US